使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Good day. Thank you for standing by. Welcome to the Heron Therapeutics second quarter 2026 earnings conference call. (Operator Instructions) Please be advised today's conference is being recorded.
大家好。感謝各位耐心等候。歡迎參加 Heron Therapeutics 2026 年第二季財報電話會議。(接線員指示) 請注意,今天的會議將被錄音。
I would now like to turn the conference over to speaker today. Melissa Jarel, please go ahead.
現在我想把會議交給今天的發言人。Melissa Jarel,請開始。
Melissa Jarel - Vice President, Legal
Melissa Jarel - Vice President, Legal
Thank you, operator. Good morning, everyone. Thank you for joining us on the Heron Therapeutics conference call today to discuss the company's financial results for the second quarter of 2026.
謝謝,接線員。各位早安。感謝各位今天參加 Heron Therapeutics 的電話會議,討論公司 2026 年第二季的財務結果。
With me today from Heron are Craig Collard, Chief Executive Officer, Ira Duarte, Executive Vice President, Chief Financial Officer, Bill Forbes, Executive Vice President, Chief Development Officer, Mark Hensley, Chief Operating Officer, and Kevin Warner, Senior Vice President, Medical Affairs Strategy and Engagement. For those of you participating via conference call, slides are made available via webcast and can also be accessed via the investor relations page of our website following the conclusion of today's call.
今天與我一同出席的 Heron 團隊成員包括:執行長 Craig Collard、執行副總裁兼財務長 Ira Duarte、執行副總裁兼開發長 Bill Forbes、營運長 Mark Hensley,以及資深副總裁(醫務事務策略與互動)Kevin Warner。透過電話參與的各位,簡報投影片已透過網路直播提供,並可於今日會議結束後至我們網站的投資人關係頁面查閱。
Before we begin, let me quickly remind you that during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. This includes remarks about the company's projections, expectations, plans, beliefs, and future performance, all of which constitute forward-looking statements for the purposes of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. These statements are based on judgment and analysis as of the date of this conference call and are subject to numerous important risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements.
在開始之前,我先快速提醒各位,本次電話會議期間公司將作出前瞻性陳述。我們提醒各位,任何非歷史事實的陳述皆屬前瞻性陳述。其中包括對公司預測、預期、計畫、信念與未來表現的評論,依 1995 年《私人證券訴訟改革法》之安全港條款之目的,均構成前瞻性陳述。這些陳述係基於本次電話會議當日的判斷與分析,並受多項重要風險與不確定性影響,可能導致實際結果與前瞻性陳述所述內容出現重大差異。
The risks and uncertainties associated with the forward-looking statements made in this conference call and webcast are described in the Safe Harbor statement in today's press release and in Heron's public periodic filings with the SEC. Except as required by law, Heron assumes no obligation to update these forward-looking statements to reflect future events or actual outcomes and does not intend to do so.
與本次電話會議及網路直播中前瞻性陳述相關的風險與不確定性,已載於今日新聞稿的安全港聲明,以及 Heron 向美國證券交易委員會(SEC)提交的公開定期申報文件中。除法律另有要求外,Heron 不承擔更新這些前瞻性陳述以反映未來事件或實際結果的義務,且無意如此。
With that, I would now like to turn the call over to Craig Collard, Chief Executive Officer of Heron.
接下來,我想把電話會議交給 Heron 的執行長 Craig Collard。
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Thanks, Melissa. Hello, everyone, and welcome to Heron Therapeutics' second-quarter 2026 earnings call.
謝謝你,Melissa。各位好,歡迎參加 Heron Therapeutics 2026 年第二季財報電話會議。
Net revenue for the quarter was $37.7 million. That is growth from the first quarter, but it is below what we expected of ourselves. CINVANTI sales were up compared to Q1 in a highly competitive market, and ZYNRELEF grew 35% year-over-year, but both were slower than we anticipated.
本季淨營收為 3,770 萬美元。這較第一季成長,但低於我們對自身的預期。在競爭激烈的市場中,CINVANTI 銷售額較第一季增加,ZYNRELEF 年增 35%,但兩者成長速度都比我們預期的慢。
Turning to slide four, let me walk through the key updates from the quarter. The acute care franchise delivered revenue growth of 44% year-over-year. ZYNRELEF grew 35%, with average daily units growing 19% year-over-year. APONVIE grew 74% year-over-year and reached 23% share of the surgical NK1 segment, up two points from the first quarter. CINVANTI came in at $21.8 million, up from $20.5 million in the first quarter. Mark will add more color in a moment to the commercial performance.
請看第 4 張投影片,我來說明本季的重點更新。急性照護產品線年增營收 44%。ZYNRELEF 成長 35%,平均每日單位數年增 19%。APONVIE 年增 74%,在手術 NK1 細分市場的市占率達 23%,較第一季提升 2 個百分點。CINVANTI 為 2,180 萬美元,高於第一季的 2,050 萬美元。稍後 Mark 會就商業表現補充更多細節。
Beyond the commercial results, what I want to spend the rest of my time on today is what we have done about the quarter and how we are proceeding moving forward. First, we reset the balance sheet. As we disclosed today, we amended our credit facility with Hercules. When the June decision from the US District Court for the District of Delaware regarding certain patents covering CINVANTI changed the outlook for the company, we went to our lender. The amendment resets our covenants through 2027 to match our new plan and reduces our principal. The terms are in the filing.
除了商業成果之外,我今天其餘時間想談的是:我們針對本季情況採取了哪些行動,以及接下來將如何推進。第一,我們重整了資產負債表。如同我們今天揭露的,我們已修訂與 Hercules 的信貸融資安排。在美國特拉華州聯邦地方法院於 6 月就涵蓋 CINVANTI 的部分專利作出裁決、改變公司前景之後,我們與放款方進行協商。此次修訂將我們的財務契約條款(covenants)重設至 2027 年,以符合新的計畫,並降低我們的本金。相關條款已載於申報文件中。
Second, we tightened our spending. After the June court decision, we paused the salesforce expansion we had planned for the second half of this year, and we are holding spending tightly while the competitive picture clarifies. Our spending decisions follow what the business demonstrates, not a plan that events have overtaken.
第二,我們收緊支出。在 6 月法院裁決後,我們暫停原本規劃於今年下半年進行的銷售團隊擴編,並在競爭態勢更明朗之前嚴格控管支出。我們的支出決策以業務實際展現的情況為依據,而不是依循已被事件超越的計畫。
Third, we are defending our oncology franchise. We have filed our appeal based on the June decision. The generic is not launched, but we are preparing for potential generic competition to CINVANTI. We have a defense strategy built around the clinical profile of the product, our customer relationships, and our contracting position, and we are executing it now before we needed it.
第三,我們正在捍衛腫瘤產品線。我們已就 6 月裁決提出上訴。目前學名藥尚未上市,但我們正為 CINVANTI 可能面臨的學名藥競爭做準備。我們的防禦策略建立在產品的臨床特性、客戶關係以及合約談判地位之上,並且我們已在真正需要之前就開始執行。
Last, we are considering strategic alternatives as we continue to execute our current plan. The company has not set a timetable for this process. There can be no assurances that it will result in any transaction, and the company does not intend to comment further on such matters unless and until it determines that additional disclosure is appropriate or required by law.
最後,在持續執行現行計畫的同時,我們也在評估策略性替代方案。公司尚未為此流程設定時間表。無法保證該流程將促成任何交易;除非且直到公司認定需要或依法必須進一步揭露,否則公司無意就此類事項再作評論。
Before I turn things over to Mark, I want to recognize the entire Heron team. This has been a demanding stretch, a hard quarter, a court decision we disagree with, and a lot of change, and this team has stayed focused on patients and customers through all of it.
在把時間交給 Mark 之前,我想肯定整個 Heron 團隊。這段期間充滿挑戰:艱難的一季、我們不同意的法院裁決,以及許多變動;但團隊始終專注於病患與客戶,貫徹到底。
I will now turn the call over to Mark to cover our commercial performance. Go ahead, Mark.
現在我把電話會議交給 Mark,說明我們的商業表現。Mark,請。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Thanks, Craig.
謝謝你,Craig。
Starting on slide 6 with the overall net sales picture. Total net sales of $37.7 million in the second quarter, up from $34.7 million in the first quarter. On the acute care side, $15.3 million combined. ZYNRELEF at $11.1 million, up from $10.2 million, and APONVIE at $4.2 million, up from $3.4 million. On the oncology side, $22.3 million combined, CINVANTI at $21.8 million and SUSTOL at $0.5 million, continuing the planned wind down. As always, ordering and channel patterns move quarter to quarter. The cleaner read on adoption is average daily units and ordering accounts, which is what I will focus on.
從第 6 張投影片開始,先看整體淨銷售概況。第二季淨銷售總額為 3,770 萬美元,高於第一季的 3,470 萬美元。急性照護方面合計 1,530 萬美元。ZYNRELEF 為 1,110 萬美元,高於 1,020 萬美元;APONVIE 為 420 萬美元,高於 340 萬美元。腫瘤方面合計 2,230 萬美元,其中 CINVANTI 為 2,180 萬美元,SUSTOL 為 50 萬美元,持續依計畫逐步縮減。一如往常,訂單與通路模式會在各季之間波動。更能清楚反映採用情況的是平均每日單位數與下單帳戶數,這也是我將著重說明的重點。
Turning to slide 7. There are two charts on this slide. Average daily units on the left, ordering accounts on the right, and both continue their upward trend. Net sales were $11.1 million, up 9% from the first quarter and up 35% from a year-ago. The number I would anchor on is demand. Average daily units grew 19% year-over-year.
接著看第 7 張投影片。這張投影片上有兩張圖表。左邊是平均每日單位數,右邊是下單帳戶數,兩者都持續呈現上升趨勢。淨銷售額為 1,110 萬美元,較第一季成長 9%,較去年同期成長 35%。我會著重的數字是需求。平均每日單位數年增 19%。
Lastly, I would add, IGNITE 2.0 is active across 3,150 accounts, up from 2,260 in IGNITE 1.0. This remains a site-by-site, case-by-case adoption curve. Unit growth was real this quarter, but it was below the rate we planned, and the work now is converting that access into cases and protocols in the accounts we are already in.
最後我再補充,IGNITE 2.0 已在 3,150 個帳戶中啟用,高於 IGNITE 1.0 的 2,260 個。這仍是一條逐站點、逐個案的採用曲線。本季的單位成長是真實的,但低於我們原先規劃的速度;目前的工作重點,是把這些存取權轉化為我們已進入之帳戶中的病例與治療流程(protocol)。
Moving to APONVIE. The same two views for APONVIE, and both charts show the steady climb. Net sales were approximately $4.2 million, up 74% from a year-ago and up 26% from the first quarter. Share in the NK1 segment reached 23%, up two points sequentially. Average daily units grew 59% year-over-year, and ordering accounts in June were up 42% from June of last year. P&T approvals now stand at 1,810 accounts, representing 6.7 million medium to high-risk procedures annually. Demand through the quarter was steady.
接著談 APONVIE。同樣以兩個視角來看 APONVIE,兩張圖都顯示穩步攀升。淨銷售額約為 420 萬美元,較去年同期成長 74%,較第一季成長 26%。在 NK1 分類中的市占率達到 23%,較前一季提升 2 個百分點。平均每日單位數年增 59%,而 6 月的下單帳戶數較去年 6 月成長 42%。P&T 核准目前達 1,810 個帳戶,代表每年 670 萬例中至高風險手術處置。本季需求維持穩定。
Now turning to CINVANTI. Average daily units on the left have held a consistent level of utilization over the past two years, and ordering accounts on the right, 1,241 in June, are in line with the 12-month average of about 1,200. Net sales were $21.8 million, up from $20.5 million in the first quarter and down about 10% from a year-ago. That year-over-year decline is the branded competition we have discussed on prior calls.
現在轉到 CINVANTI。左邊的平均每日單位數在過去兩年維持一致的使用水準;右邊的下單帳戶數在 6 月為 1,241 個,與 12 個月平均約 1,200 個一致。淨銷售額為 2,180 萬美元,高於第一季的 2,050 萬美元,但較去年同期下降約 10%。這個年減幅度來自我們在先前電話會議中討論過的品牌競品競爭。
The more recent picture is one of stability. Utilization has held steady, and share in June was 25%, in line with its 12-month average. The REIGNITE work on formulary position and our contracting relationships are the levers we control, and they are the foundation of how we would compete against any future entrant. Lastly, SUSTOL continues its planned wind down, as we've discussed on prior calls.
較近期的情況呈現穩定。使用率維持平穩,6 月市占率為 25%,與其 12 個月平均一致。REIGNITE 在處方集(formulary)位置以及我們的合約關係上的工作,是我們可掌控的槓桿,也是我們未來對抗任何新進入者的競爭基礎。最後,SUSTOL 仍依計畫持續逐步退場,如同我們在先前電話會議中所討論。
To wrap up the commercial section, ZYNRELEF average daily units grew 19% year-over-year. APONVIE reached 23% share of the NK1 segment. CINVANTI declined year-over-year against branded competition, but has held steady in recent months. The defensive contracting and formulary work is in place. That is the demand picture as it stands.
總結商業面,ZYNRELEF 的平均每日單位數年增 19%。APONVIE 在 NK1 分類的市占率達到 23%。CINVANTI 在品牌競品競爭下較去年同期下滑,但近幾個月維持穩定。防禦性的合約與處方集工作已就位。以上就是目前的需求概況。
I will now turn the call over to Ira to cover our financials. Go ahead, Ira.
接下來我把電話會議交給 Ira,請他說明我們的財務狀況。Ira,請。
Ira Duarte - Chief Financial Officer, Executive Vice President
Ira Duarte - Chief Financial Officer, Executive Vice President
Thank you, Mark.
謝謝你,Mark。
Craig has addressed the quarter directly. What is within our control is how we manage the business in response. Disciplined management of our balance sheet and our spending is what is important moving forward. Our full results are shown on this slide. I will cover the highlights.
Craig 已直接說明本季情況。我們能掌控的是,我們如何因應並管理業務。未來最重要的是對資產負債表與支出進行有紀律的管理。我們的完整結果都呈現在這張投影片上。我將說明重點。
Net revenues for the quarter were $37.7 million, compared to $34.7 million in the first quarter of 2026 and $37.2 million in the comparable prior year quarter, with gross margin coming in at 69.3%. R&D expense was $2.7 million, and SG&A expense was $25.4 million, bringing total operating expenses to $28.1 million, including stock-based compensation and depreciation.
本季淨營收為 3,770 萬美元,相較 2026 年第一季的 3,470 萬美元,以及去年同期可比季度的 3,720 萬美元;毛利率為 69.3%。研發費用為 270 萬美元,銷售、一般及行政(SG&A)費用為 2,540 萬美元,使營業費用合計達 2,810 萬美元,其中包含以股票為基礎的薪酬與折舊。
Our operating loss was $2 million, and net loss was $5.5 million, compared to a net loss of $2.4 million for the comparable prior year quarter. Adjusted EBITDA was $3.2 million, up from $2.2 million in the comparable prior year quarter.
我們的營業損失為 200 萬美元,淨損為 550 萬美元,相較去年同期可比季度的淨損 240 萬美元。調整後 EBITDA 為 320 萬美元,高於去年同期可比季度的 220 萬美元。
We ended the quarter with $42.7 million in cash equivalents and short-term investments. Following the June court decision, we negotiated an amendment with our lender that waives the June 30 covenants and resets the schedule to match our operating plan.
本季結束時,我們持有的現金等價物與短期投資為 4,270 萬美元。在 6 月法院裁決之後,我們與貸方協商並完成修訂,豁免 6 月 30 日的財務契約條款(covenants),並將時程重設以符合我們的營運計畫。
As part of that amendment, we agreed to a principal reduction that comes in two steps. $13.5 million paid at the amendment's execution plus associated fees, and a potentially further $4 million reduction scheduled on or before September 15, for a total potential principal reduction of $17.5 million.
作為該修訂的一部分,我們同意分兩步降低本金。於修訂生效時支付 1,350 萬美元本金,另加相關費用;並可能在 9 月 15 日或之前再減少 400 萬美元,合計本金最多可減少 1,750 萬美元。
Reflecting those payments, our pro forma cash is approximately $28.5 million and approximately $24.3 million after the September payment. The amendment sets monthly minimum revenue and EBITDA covenants through December 2027, along with a minimum cash covenant. The agreement is filed with our 10-Q. We are withdrawing our full year 2026 guidance of $173 million to 183 million in net product sales and $10 million to 20 million in adjusted EBITDA.
反映上述付款後,我們的備考(pro forma)現金約為 2,850 萬美元,並在 9 月付款後約為 2,430 萬美元。該修訂設定至 2027 年 12 月止的每月最低營收與 EBITDA 財務契約條款,並包含最低現金財務契約條款。該協議已隨我們的 10-Q 申報。我們撤回 2026 全年指引:淨產品銷售額 1.73 億至 1.83 億美元,以及調整後 EBITDA 1,000 萬至 2,000 萬美元。
Three things make an annual number unreliable right now. None of them is about a single quarter. First, the June court decision. The timing and terms of potential generic entry against CINVANTI, our largest product, are not events we can forecast. Any annual number would embed an assumption we are not in a position to make.
目前有三件事使得年度數字不具可靠性。它們都不是關於單一季度。第一,是 6 月的法院裁決。針對我們最大產品 CINVANTI 的潛在學名藥進入之時間點與條件,並非我們能預測的事件。任何年度數字都會內含一項我們目前無法做出的假設。
Second, the actions we took ourselves after that decision. We paused the sales force expansion that our plan had assumed for the second half. We tightened spending. Our prior guidance was built on that investment plan. It is not the plan we are currently executing on.
第二,是我們在該裁決後自行採取的行動。我們暫停了原本計畫在下半年進行的銷售團隊擴編。我們收緊支出。先前的指引是建立在那套投資計畫之上。那已不是我們目前正在執行的計畫。
Third, as Craig mentioned, we are considering strategic alternatives, which our amended credit agreement also reflects. Any one of these items on its own would make an annual number unreliable. This is a forecasting decision, not a statement about the underlying business. We would make the same decision regardless of the quarter's results. In place of guidance, we will report our cash position, our spending, and our covenant compliance every quarter.
第三,如 Craig 所提到,我們正在考慮策略性替代方案,而我們修訂後的信貸協議也反映了這點。上述任何一項單獨存在,都會使年度數字不具可靠性。這是一項預測層面的決定,而非對基本面業務的陳述。無論本季結果如何,我們都會做出相同決定。取代提供指引,我們將在每一季報告我們的現金部位、支出,以及財務契約條款遵循情況。
With that, we will open the call up for questions.
接下來,我們將開放電話會議進行提問。
Operator
Operator
(Operator Instructions) Brandon Folkes, H.C. Wainwright.
(接線員指示) Brandon Folkes,H.C. Wainwright。
Brandon Folkes - Equity Analyst
Brandon Folkes - Equity Analyst
Hi. Thanks for taking my question. Maybe just three from me. Can you elaborate on your confidence in meeting the updated debt covenants should a CINVANTI generic come to market?
嗨。感謝讓我提問。我這邊可能有三個問題。若 CINVANTI 的學名藥上市,您能否進一步說明對於達成更新後債務契約條款的信心?
Maybe just staying on CINVANTI, if and when a generic does launch, any reason the erosion should not look like the SUSTOL erosion curve? You called out it was below expectations. Can you just help us think about what is driving this below expectation performance recently? Are surgeons just not sort of warm to the detail? Are they just very sticky on the alternatives they use?
再延續 CINVANTI 的話題,若學名藥在某個時間點推出,為何侵蝕幅度不應該看起來像 SUSTOL 的侵蝕曲線?您提到其表現低於預期。能否協助我們理解近期低於預期表現的驅動因素是什麼?是外科醫師對於產品細節不太買單嗎?還是他們對目前使用的替代方案黏著度很高?
Just any drive and color in terms of what is the hurdle there on ZYNRELEF and potentially, what can a strategic partner who's well-capitalized do differently?
另外,關於 ZYNRELEF 的門檻(hurdle)是什麼,能否提供一些動因與補充說明?以及一個資本雄厚的策略夥伴可能可以用不同方式做些什麼?
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Yeah. Hi, Brandon. Let me take first on the Hercules amended agreement. The way we looked at CINVANTI, again, we took a very conservative approach with how we looked at the generic launch.
好的。嗨,Brandon。我先回答 Hercules 修訂協議的部分。我們看待 CINVANTI 時,同樣採取了非常保守的方式來評估學名藥上市。
In reality, there's a number of factors here that are at play. First of all, we don't know when the product does come to market. We know that there's some manufacturing challenges with this product as we go through them ourselves. It's a sterile process. It's an emulsion. All of that takes time to scale in order to meet market demand. Keep in mind, we're moving about 750,000-800,000 units a year. I don't think anyone wants to launch a at scale.
實際上,這裡有多項因素在發揮作用。首先,我們不知道該產品何時會上市。我們知道這個產品在製造上存在一些挑戰,我們自己也正在經歷。這是一個無菌製程。它是一種乳劑。要擴產以滿足市場需求,這些都需要時間。請記住,我們每年出貨約 75 萬到 80 萬個單位。我不認為有人會想在尚未具備規模的情況下就推出。
Secondly, there's the reimbursement piece. Do they fall under our J-code, or do they fall under their own J-code? Again, that can determine share as well. It could change sort of the market dynamic. There's a number of moving pieces, but the way we viewed this was in a really conservative kind of earlier launch scenario with Hercules on the covenant side.
第二,是給付(reimbursement)的部分。他們會歸在我們的 J-code 之下,還是會有他們自己的 J-code?同樣地,這也會影響市占。它可能改變某種市場動態。有很多變動因素,但我們在與 Hercules 討論契約條款(covenant)時,是以非常保守、偏早期上市的情境來看待。
Again, I think we're very covered there because I do think this may take a bit longer than maybe we modeled out. I think from that standpoint, our lenders felt very comfortable. I'll turn it over to Mark on the second piece about ZYNRELEF and kind of what's going on with the quarter.
再次強調,我認為我們在那方面的保障非常充足,因為我確實認為這可能會比我們模型推估的時間更久一些。從這個角度來看,我們的放款人感到非常放心。我把第二部分、關於 ZYNRELEF 以及本季狀況的問題交給 Mark。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
Yeah, thanks for the question, Brandon. On ZYNRELEF, the product grew 9% quarter-over-quarter. As you're aware, in Q1, the market itself was down, we expected to recover from that quite strongly in Q2. We didn't quite get to our expectations in the second quarter, certainly that's on us to rectify.
好的,謝謝你的提問,Brandon。關於 ZYNRELEF,該產品季對季成長 9%。如你所知,第一季市場本身是下滑的,我們原本預期第二季會相當強勁地復甦。第二季我們沒有完全達到預期,這當然是我們需要修正的地方。
I wouldn't point to anything necessarily about the product. Certainly, the market itself is a little bit slow this time of year, as you can look back at slide 7 in the earnings deck, you see a really nice run-up in the back half of the year for the market and for ZYNRELEF and other products in that market. We still expect that to occur. Certainly, Q2 is on us from an execution perspective, and we'll work to fix that in the third quarter.
我不會特別把原因指向產品本身。當然,每年這個時節市場本來就稍微偏慢;你可以回頭看財報簡報第 7 頁,會看到在下半年市場、ZYNRELEF 以及該市場的其他產品都有很不錯的上升走勢。我們仍然預期那會發生。當然,就執行面而言,第二季的表現是我們的責任,我們會在第三季努力改善。
Operator
Operator
Serge Belanger, Needham.
Serge Belanger,Needham。
Serge Belanger - Analyst
Serge Belanger - Analyst
I guess first one for Craig on potential generic CINVANTI. I know there's still a lack of clarity on a potential launch here, but I believe you have a couple settlement agreements around CINVANTI with some other players. Curious what the impact would be for those potential launches on those players if Azurity does launch a generic product.
我想第一個問題給 Craig,關於 CINVANTI 潛在的學名藥。我知道目前對於可能的上市仍缺乏明確性,但我相信你們與其他一些業者就 CINVANTI 有幾項和解協議。我想了解的是,如果 Azurity 推出學名藥產品,對於那些業者依協議可能進行的上市會有什麼影響?
Secondly, regarding ZYNRELEF, maybe for Mark, just curious what you're seeing in terms of surgical volumes and just the overall volume of procedures over the second quarter. I believe your competitor reported some macro volatility that impacted healthcare spending. Just curious if you're seeing kind of the same thing. Thanks.
第二,關於 ZYNRELEF,可能問 Mark:想了解你們在第二季看到的手術量,以及整體手術程序量的情況。我相信你們的競爭對手提到一些總體波動影響了醫療支出。想請問你們是否也看到類似情況。謝謝。
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
Yeah, Serge, regarding CINVANTI, whether it launches or doesn't launch, it will have no impact at all on the settlement. That should not change.
好的,Serge,關於 CINVANTI,不論它是否上市,都不會對和解協議造成任何影響。這點不會改變。
Mark Hensley - Chief Operating Officer, Executive Vice President
Mark Hensley - Chief Operating Officer, Executive Vice President
As far as ZYNRELEF goes, kind of macro impacts, look, I think we still continue to make progress on P&T wins throughout the quarter. Maybe we weren't as impacted as much by that situation, or at least I didn't hear that much about it in particular. Really, it's just about time of pull-through. We were a little bit slower on a few things in the quarter than we expected, and certainly hope to see those continue to pull through in the back half of the year.
至於 ZYNRELEF 的總體影響,坦白說,我認為我們整個季度仍持續在 P&T(藥事與治療委員會)准入方面取得進展。也許我們沒有受到那種情況太大的影響,至少我沒有特別聽到太多相關回饋。重點其實在於拉動(pull-through)所需的時間。本季在幾件事情上我們比預期慢了一些,當然也希望在下半年看到這些持續轉化。
Operator
Operator
I'm not showing any further questions at this time. I'd like to turn the call back over to Craig for any further remarks.
目前我這邊沒有看到其他提問。我想把電話會議交回給 Craig,請他做任何補充說明。
Craig Collard - Chief Executive Officer, Director
Craig Collard - Chief Executive Officer, Director
No, thanks everyone for joining the call this quarter, and we'll talk to you next quarter. Thank you.
沒有了,謝謝各位參加本季的電話會議,我們下季再聊。謝謝。
Operator
Operator
Thank you, ladies and gentlemen. This concludes today's presentation. We thank you for your participation. You may now disconnect, and have a wonderful day.
謝謝各位女士、先生。今天的簡報到此結束。感謝各位的參與。您現在可以掛線,祝您有美好的一天。